Indivior PLC released a business update for investors, highlighting several key areas. Firstly, the company adjusted its financial expectations for the second quarter and full year 2024, citing adverse market conditions affecting the growth of its medication SUBLOCADE. Despite this, the company maintains its medium-term financial outlook, anticipating double-digit net revenue growth and operating margin expansion. Secondly, Indivior announced the discontinuation of sales and marketing for PERSERIS due to expected financial viability issues arising from increased payor management in the category. This decision is expected to result in a reduction of approximately 130 employees and incur total charges of $65 million. Thirdly, the company provided preliminary net revenue expectations for the second quarter, with SUBLOCADE net revenue falling below expectations due to continued Medicaid disenrollments and lower-than-anticipated stocking levels. Fourthly, Indivior updated its full-year 2024 guidance, reflecting the cessation of PERSERIS sales and marketing, and reaffirmed its long-term net revenue targets. Finally, the company disclosed a settlement agreement with end payor plaintiffs in the Health Care Services Corp (HCSC) consolidated cases for $85 million, resolving the litigation.